Alwaleed Philanthropies, a charitable and philanthropic organisation, is investing USD5m in its collaboration with Gavi, the Vaccine Alliance, it was reported on Sunday.
The commitment will offer extra funding between 2020 and 2024 to support organisations known by Gavi as 'pacesetters' that are developing new innovations to improve vaccine access and delivery, particularly in urban areas. The investment will be made through Gavi's INFUSE initiative (Innovation for Uptake, Scale and Equity in Immunisation), which identifies these 'pacesetters', offers funding and support for them, and connects them to authorities in countries that required vaccination support.
The grant is part of a range of efforts by Alwaleed Philanthropies to improve routine immunisation and contributes to Gavi's mission to ensure that every child is immunised with basic life-saving vaccines, no matter where they live, and builds on the original USD1m investment made in 2015 to support vaccines in Timor Leste, Kiribati, Armenia, Azerbaijan, Moldova, Guyana for the 2016-2020 programme.
Anixa Biosciences transfers breast cancer vaccine IND from Cleveland Clinic
Sanofi completes acquisition of Vicebio to expand respiratory vaccines portfolio
Valneva reports positive final Phase 2 results for Lyme disease vaccine VLA15
Lunai Bioworks receives first LOI to license next-generation immune cell therapy
BioNet receives positive opinion from EMA for VacPertagen marketing authorisation in EU
Anixa Biosciences secures U.S. Patent strengthening breast cancer vaccine IP into mid 2040s
PharmaJet® and EVA Pharma Partner to Scale Needle-free Polio Immunisation Across Egypt
Frontier IP portfolio company achieves breakthrough in livestock vaccine trials
GC Biopharma's Phase 2 clinical trial results for BARYTHRAX published in Vaccine
Bavarian Nordic secures new EU contract for up to 8 million smallpox and mpox vaccine doses